EUVIMEDEUVIMED entdecken
Crossref

Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma

H.J. Li, L. Zi-Ling, W. Pei-Ihen, M. Nicola, H. Kuo-Yen, Y. Pan-Chyr

European Journal of Cancer · 2026-11 · 248 · 117522

DOI: 10.1016/j.ejca.2026.117522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von H.J. Li und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Li, H., Zi-Ling, L., Pei-Ihen, W., Nicola, M., Kuo-Yen, H., & Pan-Chyr, Y. (2026). Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma. European Journal of Cancer, 248, 117522. https://doi.org/10.1016/j.ejca.2026.117522

Vancouver

Li H, Zi-Ling L, Pei-Ihen W, Nicola M, Kuo-Yen H, Pan-Chyr Y. Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma. European Journal of Cancer. 2026;248:117522. doi:10.1016/j.ejca.2026.117522

BibTeX
@article{Li2026,
  author = {Li, H.J. and Zi-Ling, L. and Pei-Ihen, W. and Nicola, M. and Kuo-Yen, H. and Pan-Chyr, Y.},
  title = {Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117522},
  doi = {10.1016/j.ejca.2026.117522}
}
Kostenlos starten →